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Introduction. Experiments on genetically modiﬁed animals have discovered a complex cross-regulation between adipokines
(leptin, adiponectin) and osteocalcin. The relationships between these molecules in human osteoporosis are still unclear. We
evaluated the hypothesis of a bidirectional link between adipokines and osteocalcin. Materials and Methods. In a cross-sectional
study of 294 older patients with osteoporotic hip fracture, we estimated serum concentrations of leptin, adiponectin, resistin,
osteocalcin, parameters of mineral metabolism, and renal function. Results. After adjustment for multiple potential confounders,
serum osteocalcin concentration was inversely associated with resistin and positively with leptin, leptin/resistin ratio, and
adiponectin/resistin ratio. In multivariate regression models, osteocalcin was an independent predictor of serum leptin, resistin,
leptin/resistin, and adiponectin/resistin ratios. Conclusions. Our data support the bidirectional regulation between osteocalcin
and adipokines, but contrary to the genetically modiﬁed animal models, in older subjects with osteoporotic hip fracture, serum
osteocalcin is positively associated with leptin and inversely with resistin.
1.Introduction
Over the past two decades, it has been convincingly shown
that adipose tissue is an active endocrine organ which
produces a number of biologically active molecules named
adipokines. More recently, the endocrine function of the
skeleton and its important role in metabolic homeostasis has
beenrevealed[1,2].Mainlythroughmousegeneticmeansby
analysingloss-of-functionmodels,theexistenceofacomplex
bilateral hormonal link (crosstalk) between bone and energy
metabolism has been discovered [1–4]. According to the
current paradigm, bone remodelling and energy metabolism
are coregulated by adipocyte-derived hormones, leptin, and
adiponectin,andthefeedbackloopbetweenboneandenergy
metabolism is mediated by osteocalcin (OC), an osteoblast-
speciﬁc protein. The biological importance of tight connec-
tions between adipose tissue and bone remodelling is further
supported by the fact that adipocytes and osteoblasts are
d e r i v e df r o mac o m m o nm e s e n c h y m a lp r o g e n i t o rc e l l[ 5],
leptinandadiponectinareexpressedinosteoblasts[6–8]and
OC in human adipocytes [9]. A crosstalk between signalling
pathway regulating adipocyte and osteoblast diﬀerentiation
has also been recently described [10].
Results of experimental studies on reciprocal bone-en-
ergy metabolism relationships mediated by adipokines and
OC are fairly consistent. However, clinical data on the
association between circulating leptin and adiponectin levels
and OC are controversial. Previous human studies that have
evaluated the relationship between leptin and OC yielded
conﬂicting results, showing either no correlation [11–16],
positive [17], or negative correlation [18–21]. Similarly,
some studies reported a positive association between serum
adiponectin and OC [22–27], whereas other studies were
not able to demonstrate a signiﬁcant and independent re-
lationship [16, 20, 28–30].
Emerging evidence has shown that resistin, a peptide
hormone classiﬁed as an adipokine, although in humans it is
mainly produced by mononuclear cells and macrophages, is2 International Journal of Endocrinology
important in regulating insulin resistance, diabetes, inﬂam-
matory processes, immunity, and bone metabolism [17, 31–
34]. However, the interrelations between resistin and OC
have not been characterised.
In the above-mentioned studies, such factors as serum
calcium, phosphate, magnesium, 25-hydroxyvitamin D
(25(OH)D), parathyroid hormone (PTH), renal status, and
age, known to inﬂuence both bone metabolism and circu-
lating adipokines, have rarely been measured and analysed.
Lack of assessment of several adipokines simultaneously,
diﬀerence in study populations and the dual nature of
leptin’s eﬀect on the skeleton (central antiosteogenic [35]
and peripheral osteogenic [5]) may also contribute to the in-
consistency in human data.
There are only a few studies evaluating leptin [36,
37] and adiponectin [38] in patients with hip fracture
(HF), but no research has been carried out showing the
relationship between adipokines and OC in these patients.
It remains to be determined whether the phenomenon
of bidirectional adipokine-OC interaction is involved in
human osteoporosis. Therefore, the aim of the present study
was to asses in older patients with HF the association
of leptin, adiponectin, and resistin, the three most widely
investigated adipokines, with OC, and to examine whether
OC is a signiﬁcant and independent predictor of circulating
adipokine levels. We also analysed the combined eﬀect of
adipokines using their ratios, since it has been suggested that
metabolic functions of adipokines, especially of leptin and
adiponectin, are complementary, and the leptin/adiponectin
and adiponectin/resistin ratios are better clinical indicators
[39–43].
2. Patientsand Methods
2.1. Patients. A total of 294 consecutive older patients (≥60
years of age, mean age 82.1 ± 8.0 years) with low-trauma
osteoporotic HF were included in this study. Data were
obtained from a prospective electronic database on all adult
patients with fracture of the upper femur admitted to the
orthopaedic ward of The Canberra Hospital (Canberra,
AustralianCapitalTerritory,Australia),auniversity-aﬃliated
tertiary care centre. Exclusion criteria were subtrochanteric
andshaftfracture,age<60years,hightrauma,andpatholog-
ical HF due to primary or metastatic bone cancer, multiple
myeloma, Paget disease, or primary hyperparathyroidism.
Sociodemographic, anthropometric, clinical (HF type, co-
morbidities, complications, medication use) and laboratory
data were recorded.
Informed consent was obtained from all patients or their
carers. The study has approval of the local Research Ethics
Committee.
2.2. Laboratory Measurements. In all patients, antecubital
venous blood samples were collected after overnight fast
within 48 hours of arrival at the Emergency Department.
Routine haematological and biochemical assessments were
performed by standardised methods on autoanalysers at the
day of collection. For assays of OC, leptin, adiponectin,
and resistin serum samples were frozen in liquid nitrogen
and stored at −70◦C, subsequently thawed and analysed
in a single batch using commercially available kits. Serum
levels of OC were determined by electrochemiluminescence
immunoassay (Elecsys 1010; Roche Diagnostics, IN, USA;
analytical sensitivity 0.5ng/mL, interassay coeﬃcient of
variation (CV) 2.1–3.1%, intraassay CV < 3%), leptin
by enzyme-linked immunosorbent assay (ELISA) method
(Diagnostic System Laboratories, Webster, TX, USA; sensi-
tivity 0.05ng/mL, interassay CV 3.4–5.5%, intraassay CV <
6%), total adiponectin and resistin by human ELISA kits
(B-Bridge International, Mountain View, CA, USA; for
adiponectin sensitivity 0.5ng/mL, intraassay CV 3.2–7.3%,
intraassay CV < 6%; for resistin sensitivity 0.03ng/mL,
interassay CV 4.5–7.2%, intraassay CV < 5%). All assays
were performed with kits of the same lot number.
Serum levels of 25(OH)D were determined by a radioim-
munoassay kit (Dia Sorin, Stillwater, MN, USA; sensitiv-
ity 0.7pmol/L, interassay CV5.9–9.4%, intraassay CV <
11.5%), intact PTH by solid-phase two-site chemilumines-
centenzyme-linkedimmunometricassayonaDPCImmulite
2000 analyzer (Diagnostic Products, Los Angeles, CA, USA;
sensitivity 0.07pmol/L, interassay CV 6.2–7.0%, intraassay
CV < 6%). Serum calcium concentration was corrected
for serum albumin. Glomerular ﬁltration rate (eGFR) was
estimated by the formula [44].
2.3. Statistical Analyses. All analyses were performed using
Stata software (version 10; StataCorp, College Station, TX,
USA). The summary statistics are presented as the mean
± standard deviation for continuous variables and as the
number (percentages) for categorical variables. Continuous
variables with a skewed distribution were logarithmically
transformed before being used in correlation analyses. The
relationships between variables were examined by Pearson’s
linear correlation test and multivariate logistic regression
analyses. P<0.05 (two-sided) was considered statistically
signiﬁcant. To assess the potential eﬀect of multiple compar-
isons and the signiﬁcance of multicollinearity phenomena
in multivariate regression analyses, Bonferroni’s and Sidak’s
corrections were used and the variance inﬂation factor was
calculated.
3. Results
3.1. Patient Characteristics. The demographic and clinical
characteristics of the study patients are shown in Table 1.
There were 212 (72.1%) women and 82 (27.9%) men.
Women were found to be slightly older than men (82.6 ±
7.7v e r s u s8 0 .6 ± 8.3y e a r s ,P = 0.053). The HF was of
cervical type in 52% and of trochanteric in 48% of patients.
The mean (±SD) values of serum 25(OH)D and PTH
were 37.2 ± 18.0nmol/L and 6.9 ± 5.6pmol/L, respectively.
Vitamin D deﬁciency (25(OH)D < 50nmol/L was found
in 84.6% of females and 67.5% of males (P<0.008)
and secondary hyperparathyroidism (PTH > 6.8pmol/L)
in 39.4% and 25.3%, respectively (P = 0.028). The mean
serum osteocalcin level was 17.2 ± 15.2ng/mL. The serumInternational Journal of Endocrinology 3
Table 1: Demographic and clinical characteristics of the study
patients with hip fracture (n = 294).
Characteristic
Age, years (mean ± SD) 82.2 ± 7.9
Females, % 72.1
Comorbidities:
Hypertension, % 54.0
CAD, % 21.2
Previous myocardial
infarction, %
5.3
Atrial ﬁbrillation, % 13.2
History of stroke, % 14.3
TIA, % 7.4
Type 2 DM, % 18.8
Dementia, % 27.8
Parkinson’s disease 4.4
CKD stage ≥ 3 42.6
COPD 11.8
Malnutrition 33.8
CAD, coronary artery disease; TIA, transient ischaemic attack; DM,
diabetes mellitus; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease.
osteocalcinlevelswerelow(<14ng/mL)in53.3%ofpatients.
The osteocalcin concentrations did not diﬀer signiﬁcantly
with respect to gender or HF type. The main concen-
trations of serum leptin, adiponectin, and resistin were
18.4±23.2ng/mL,17.5±7.4ng/mL,and18.7±10.5ng/mL,
respectively. Women had signiﬁcantly higher mean serum
concentrationsofleptin(21.1±24.3versus11.7±18.6ng/mL,
P = 0.002), adiponectin (18.3 ±7.1v e r s u s1 5 .6 ±7.6ng/mL,
P = 0.007), leptin/resistin ratio (1.6 ± 2.3v e r s u s0 .8 ± 1,
P = 0.006), and PTH (7.4 ± 6.1v e r s u s5 .5 ± 3.5pmol/L,
P = 0.009), but lower levels of 25(OH)D (35.3 ± 17.6v e r s u s
42.4±18.2nmol/L,P = 0.009),phosphate(0.89±0.29versus
1.07 ± 075nmol/L, P = 0.003), magnesium (0.76 ± 0.13
versus 0.81 ± 0.12nmol/L, P = 0.008), and eGFR (62.7 ±
22 versus 71.2 ± 26.4mL/min./1.73m2, P = 0.006). Mean
serum concentrations of resistin, leptin/adiponectin, and
adiponectin/resistin ratios, osteocalcin, calcium (corrected
for albumin), TSH, albumin, and haemoglobin in women
and men did not diﬀer.
Malnutrition deﬁned as serum leptin concentration
<4ng/mL in males and <6.5ng/mL in females [45]w a s
observed in 33.8% of patients (equal in both sexes). The
malnourished group compared to the rest of the cohort was
older (83.6 ± 7.8v e r s u s8 1 .2 ± 8.0y e a r s ;P = 0.015) and as
would be expected had higher serum levels of adiponectin
(19.3 ± 6.6v e r s u s1 6 .5 ± 7.5ng/mL;P = 0.035) and lower
levels of leptin (2.9 ± 1.3v e r s u s2 6 .5 ± 25.0ng/mL; P<
0.001), haemoglobin (121.3 ± 16.3 versus 126.3 ± 17.4g/L;
P = 0.021), leptin/adiponectin (0.17 versus 2.13; P<0.001),
and leptin/resistin (0.22 versus 1.94; P<0.001) ratios; OC
levels were also lower, however, the diﬀerence did not reach
statistical signiﬁcance (15.3 ± 9.7v e r s u s1 8 .2 ± 17.3ng/mL;
P = 0.117).
Patients with cervical compared to trochanteric HF had
higher serum levels of adiponectin (18.5 ± 7.3v e r s u s1 6 .3 ±
7.3ng/mL,P = 0.019) and resistin (20.1 ± 10.5 versus 16.9±
ng/mL, P = 0.014), lower leptin/resistin ratio (1.1 ± 1.4
versus 1.7 ± 2.6, P = 0.025), and PTH concentrations (5.9 ±
3.6v e r s u s8 .0 ± 6.9pmol/L,P = 0.001), but did not diﬀer
signiﬁcantly regarding other parameters.
3.2. Correlations of Adipokines with Serum Osteocalcin, Pa-
rameters of Mineral Metabolism, Renal Status, and Age. Pear-
son correlation analysis performed with log-transformed
variables revealed that leptin correlated positively with
osteocalcin (r = 0.123, P = 0.038), BMI (r = 0.210,
P = 0.001), and haemoglobin (r = 0.188, P = 0.001)
and inversely with adiponectin (r =− 0.178, P = 0.005),
phosphate (r =− 0.161, P = 0.007), and age (r =− 0.154,
P = 0.009). Adiponectin correlated positively with PTH
(r = 0.193, P = 0.002) and age (r = 0.251, P = 0.001) and
negatively with BMI (r =− 0.170, P = 0.005).
Resistin correlated positively with age (r = 0.156, P =
0.013) and negatively with serum magnesium (r =− 0.198,
P = 0.002) and eGFR (r =− 0.126, P = 0.044). Serum
osteocalcin correlated positively also with leptin/adiponectin
ratio (r = 0.129, P = 0.041), leptin/resistin ratio (r = 0.166,
P = 0.008), calcium (r = 0.169, P = 0.004), phosphate
(r = 0.129, P = 0.003), magnesium (r = 0.124, P = 0.038),
and age (r = 0.152, P = 0.010) and negatively with eGFR
(r =− 0.388, P = 0.001) and 25(OH)D (r =− 0.127,
P = 0.037).
3.3.Adipokines and TheirRatios asIndependent Determinants
of Serum Osteocalcin. Multiple regression analyses were
performed to evaluate which individual adipokine or their
ratios are independently associated with serum osteocal-
cin. As shown in Table 2, there was a signiﬁcant positive
correlation between serum log-leptin and log-osteocalcin
before and after multiple adjustments. No relationship was
found between log-transformed serum adiponectin and log-
osteocalcin. Serum log-resistin was negatively and signiﬁ-
cantlyassociatedwithlog-osteocalcinonlyafteradjusting for
age,sex,BMI,HFtype,25(OH)D,andPTH.Thisassociation
remained signiﬁcant after all further adjustments. In the
ﬁnal regression when all three adipokines were used in place
of one, the independent determinants of serum osteocalcin
were leptin (P = 0.040), resistin (P = 0.018), age (P =
0.018), and eGFR (P<0.001). The model explained
39.5% of the variance in OC. Taking into account that
type 2 diabetes mellitus (DM), hypertension, and other
cardiovascular diseases which are common in the elderly
population (Table 1) are known to be associated with dys-
regulation in adipokine metabolism, we further adjusted our
models for these comorbidities (yes/no). These adjustments
did not appreciably change the estimates for OC-leptin
and OC-adiponectin associations. Neither hypertension (per
se) nor any cardiovascular disease aﬀected the OC-resistin
relationship. However, addition of type 2 DM to the models4 International Journal of Endocrinology
Table 2: Associations of serum leptin, adiponectin, and resistin with serum osteocalcin as dependent variable in linear regression models.
Adjustments
Leptin Adiponectin Resistin
β P βPβP
Unadjusted 0.071 0.038 −0.015 0.859 −0.064 0.372
+Age, sex, BMI 0.093 0.008 −0.087 0.329 −0.099 0.167
+HF type 0.093 0.009 −0.084 0.350 −0.097 0.182
+25(OH)D 0.081 0.023 −0.126 .0162 −0.138 0.055
+PTH 0.080 0.024 −0.138 0.129 −0.169 0.022
+Ca, Mg, PO4 0.079 0.027 −0.123 0.072 −0.178 0.019
+eGFR 0.055 0.105 −0.073 0.406 −0.162 0.026
+Haemoglobin 0.076 0.046 −0.075 0.394 −0.162 0.026
+Two other
adipokines
0.077 0.040 −0.051 0.567 −0.173 0.018
+Type 2 DM 0.090 0.018 −0.053 0.551 −0.119 0.126
+Hypertension∗ 0.078 0.046 −0.055 0.544 −0.173 0.021
+CVD (any)∗ 0.090 0.023 −0.059 0.575 −0.156 0.037
+CVD (any) 0.099 0.014 −0.061 0.507 −0.104 0.191
Leptin, adiponectin, resistin, and osteocalcin were included in models as logarithmically transformed variables; +indicates adjustments for all covariates in
the above model; ∗indicates adjustments for all covariates in the above model except type 2 DM; β standard regression coeﬃcient; P probability value; DM,
diabetes mellitus; CVD, cardiovascular disease; BMI, body mass index; HF, hip fracture; 25(OH)D, 25 hydroxy vitamin D; PTH, parathyroid hormone; Ca,
calcium; Mg, magnesium; PO4, phosphate; eGFR, estimated glomerular ﬁltration rate.
Table 3: Associations of serum adipokine ratios with serum osteocalcin as dependent variable in linear regression models.
Adjustments
Leptin/Adiponectin ratio Leptin/Resistin ratio Adiponectin/Resistin ratio
β P β P β P
Unadjusted 0.037 0.041 0.055 0.008 0.047 0.098
+Age, sex, BMI 0.048 0.007 0.079 0.000 0.044 0.114
+HF type 0.048 0.008 0.079 0.000 0.044 0.115
+25(OH)D 0.039 0.028 0.071 0.001 0.045 0.095
+PTH 0.042 0.019 0.075 0.000 0.048 0.076
+Ca, Mg, PO4 0.041 0.023 0.068 0.002 0.048 0.084
+eGFR 0.031 0.074 0.057 0.007 0.052 0.042
+Haemoglobin 0.033 0.064 0.061 0.005 0.052 0.043
+type 2 DM 0.034 0.055 0.058 0.006 0.035 0.426
+Hypertension∗ 0.034 0.060 0.061 0.005 0.053 0.044
+CVD (any)∗ 0.034 0.062 0.060 0.005 0.051 0.050
+CVD (any) 0.034 0.057 0.057 0.009 0.038 0.453
Osteocalcin was included in the models as a logarithmically transformed variable. +indicates adjustments for all covariates in the above model; ∗Indicates
adjustments for all covariates in the above model except type 2 DM; β standard regression coeﬃcient; P probability value; DM, diabetes mellitus; CVD,
cardiovascular disease; BMI, body mass index; HF, hip fracture; 25(OH)D, 25 hydroxy vitamin D; PTH, parathyroid hormone; Ca, calcium; Mg, magnesium;
PO4, phosphate; eGFR, estimated glomerular ﬁltration rate.
with resistin made this association nonsigniﬁcant, indicating
that higher resistin levels are incorporated in type 2 DM.
Indeed,thepatientswithtype2DMhavesigniﬁcantlyhigher
serum resistin concentrations (+29.2%) than the rest of the
cohort (23.0 ± 11.2v e r s u s1 7 .8 ±10.0ng/mL,P = 0.010).
Results of multivariate regression modelling testing the
hypothesis that individual adipokine ratios are associ-
ated with serum osteocalcin are shown in Table 3.A si t
would be expected, there was a strong positive correlation
between leptin/resistin ratio and serum log-osteocalcin, and
it remained signiﬁcant after all adjustments. There was also
a positive association between leptin/adiponectin ratio and
log-osteocalcin before and after adjusting for age, sex, BMI,
HF type, and parameters of mineral metabolism, but this
association lost signiﬁcance when further adjusted for eGFR
and haemoglobin as well as for comorbidities. In contrast,
the adiponectin/resistin ratio was signiﬁcantly associated
with serum log-osteocalcin only in models near fully or fully
adjusted.
Taken together, these results indicate that leptin and
resistin are independent positive and negative, respec-
tively, determinants of serum OC. Not surprisingly, theInternational Journal of Endocrinology 5
Table 4: Independent factors associated with serum adipokine levels in older patients with hip fracture (multivariate linear regression
models).
Leptin Adiponectin Resistin
β P β P β P
Osteocalcin 0.297 0.014 −0.036 0.507 −0.133 0.037
Age −0.037 0.001 0.015 0.002 0.011 0.050
Sex (m) −0.598 0.001 −0.184 0.020 0.074 0.437
HF type 0.215 0.163 −0.209 0.002 −0.208 0.010
25(OH)D −0.006 0.129 0.003 0.155 0.002 0.417
PTH 0.001 0.949 0.020 0.003 0.021 0.006
Ca −1.056 0.090 −0.216 0.436 0.617 0.059
PO4 −0.273 0.057 0.049 0.439 −0.059 0.443
Mg 0.323 0.581 −0.307 0.236 −0.924 0.003
eGFR −0.009 0.024 0.0011 0.430 −0.001 0.829
Adiponectin −0.331 0.036 —— −0.045 0.621
Leptin —— −0.065 0.036 0.003 0.945
Resistin −0.063 0.649 −0.018 0.769 — —
Haemoglobin 0.019 0.036 −0.002 0.429 −0.001 0.767
Type 2 DM 0.232 0.269 −0.120 0.197 0.117 0.261
CVD (any) 0.449 0.004 −0.016 0.827 0.103 0.224
Leptin, adiponectin, resistin and osteocalcin were included in models as logarithmically transformed variables; β standard regression coeﬃcient; P probability
value; BMI, body mass index; HF, hip fracture; 25(OH)D, 25 hydroxy vitamin D; PTH, parathyroid hormone; Ca, calcium; Mg, magnesium; PO4, phosphate;
eGFR, estimated glomerular ﬁltration rate; DM, diabetes mellitus; CVD, cardiovascular disease.
leptin/resistin ratio signiﬁcantly and positively correlated
with OC predicting 39.2% of the total variance in OC,
and the adiponectin/resistin ratio could predict 37.4% of
the variance. The partial associations between the lep-
tin/adiponectin, adiponectin/resistin ratios and, OC conﬁrm
the independent eﬀects of leptin and resistin on serum OC
and show the inﬂuence of other factors related mainly to
adiponectin.
3.4. Independent Factors Associated with Circulating Ad-
ipokines and Their Ratios. We next asked which factors
are independent determinants of serum adipokine levels
and their ratios. On multiple linear regression analyses
and in keeping with previous results, serum OC was a
signiﬁcant predictor of both leptin and resistin, but not
adiponectin (Table 4). Age was an independent determinant
of each of the three adipokines. None of the adipokines was
signiﬁcantly and independently associated with 25(OH)D.
Other parameters independently associated with circulat-
ing leptin were male sex, eGFR, adiponectin, (all three
inversely), haemoglobin, and CVD (both positively). Serum
resistin levels were independently associated with PTH
(positively), trochanteric HF type, and serum magnesium
(both inversely).
Independent predictors of the three adipokine ratios
are shown in Table 5. OC was signiﬁcantly independently
associatedwithleptin/resistin andadiponectin/resistin ratios
but not with the leptin/adiponectin ratio. Age, male sex
(both negatively), trochanteric HF type, and haemoglobin
(both positively) were the other parameters independently
associated with the leptin/resistin ratio; the model explained
44.5% of variance in this ratio. OC was also the only
independent predictor of the adiponectin/resistin ratio, but
in fully adjusted model it accounted only 5.5% of variance.
4. Discussion
The main ﬁndings of this study of 294 consecutive un-
selected older patients with low-trauma HF are statisti-
cally signiﬁcant correlations between leptin, resistin, and
OC indicating complex interactions between adipocytes/
monocytes/macrophages and osteoblasts. These have been
demonstrated by simultaneous measurementsof three major
circulating adipokines (leptin, adiponectin, and resistin),
their ratios, and serum OC. Multiple linear regression
models adjusted for age, gender, BMI, HF type, key factors,
or mineral metabolism (calcium, phosphate, magnesium,
25(OH)D, PTH), renal function, and haemoglobin showed
that serum OC levels were signiﬁcantly and positively associ-
ated with leptin and negatively with resistin concentrations,
but not related to circulating adiponectin levels. Leptin,
resistin (or leptin/resistin ratio), age, and eGFR were the
onlyindependentpredictorsofserumOClevelscontributing
to 39.5% of OC variance. On the other hand, OC was an
independent determinant of serum leptin and resistin levels,
as well as leptin/resistin and adiponectin/resistin ratios.
Although caution is needed when interpreting results of
a cross-sectional study, our data may suggest the presence of
adipokine-OCloops,speciﬁcally,leptinincreasesandresistin
decreases OC secretion by osteoblasts, whereas circulating
OC inﬂuences leptin (positive feedback loop) and resistin6 International Journal of Endocrinology
Table 5: Independent factors associated with serum adipokine ratios in older patients with hip fracture (multivariate linear regression
models).
Leptin/Adiponectin ratio Leptin/Resistin ratio Adiponectin/Resistin ratio
β P β P β P
Osteocalcin 0.511 0.057 0.577 0.009 0.354 0.044
Age −0.082 0.000 −0.094 0.000 0.010 0.521
Sex (m) −0.763 0.051 −0.107 0.001 −0.432 0.096
HF type 0.898 0.007 0.782 0.004 −0.028 0.897
25(OH)D 0.024 0.013 −0.010 0.175 0.001 0.910
PTH −0.082 0.018 −0.047 0.095 −0.020 0.357
Ca −0.205 0.882 −0.329 0.771 −1.086 0.220
PO4 −0.478 0.136 −0.275 0.293 0.121 0.570
Mg 2.077 0.108 2.011 0.058 1.270 0.140
eGFR −0.015 0.095 −0.011 0.127 0.007 0.208
Haemoglobin 0.026 0.008 0.026 0.001 −0.002 0.728
Type 2 DM −0.005 0.991 −0.110 0.775 −0.290 0.127
CVD (any) 0.232 0.508 0.141 0.622 −0.169 0.234
Leptin, adiponectin, resistin and osteocalcin were included in models as logarithmically transformed variables; β standard regression coeﬃcient; P probability
value; BMI, body mass index; HF, hip fracture; 25(OH)D, 25 hydroxy vitamin D; PTH, parathyroid hormone; Ca, calcium; Mg, magnesium; PO4, phosphate;
eGFR, estimated glomerular ﬁltration rate; DM, diabetes mellitus; CVD, cardiovascular disease.
(negative feedback loop) production. These two counter-
balancing circuits seem to be important components of
a complex homeostatic framework. These results are in
line with the current concept that eﬃcient maintenance
of metabolic homeostasis depends on interaction between
adipose tissue/energy metabolism and skeleton [1–4], but
the directions of some associations observed in this as in
other clinical studies were opposite to that reported in
experimental animals (genetically modiﬁed obese rodents).
Although adipokines, especially leptin and adiponectin,
two pleiotropic hormones involved in regulation of a large
variety of physiological processes, have been extensively
studied in recent years, current data on their eﬀects on
bone and the adipokine-OC interactions in humans are
controversial and the underlying mechanisms not fully
understood.
It is now well acknowledged that the eﬀect of leptin on
bone is complex and includes diﬀerent pathways: central
inhibition of bone formation through the hypothalamus
and brainstem involving β adrenergic, neuromedin U, neu-
ropeptide Y, cocaine, and amphetamine-related transcript
and serotoninergic systems [35, 46, 47] and direct periph-
eral (local) enhancement of osteoblastic cell diﬀerentiation,
proliferation, and bone mineralization [5, 7]. Results from
studies of the bone phenotype in animals with leptin
deﬁciency (ob/ob) and leptin receptor deﬁciency (dbldb,
fa/fa) are conﬂicting. While several groups concluded that
leptin acts as a positive regulator of bone formation [48,
49], other suggested a negative (through the hypothalamus)
eﬀect on the skeleton [35, 47]. In humans, both positive
and negative correlations between leptin and bone mineral
density (BMD) [47], as well as with OC [11–21], have been
reported.
Our ﬁnding that serum leptin is associated with OC is
consistent with clinical observations that leptin positively
correlatedwithOC[17]andBMD[15,18,50,51]indiﬀerent
settings, whereas decrease of OC in bone predispose to HF
[52]. Our results are also supported by a strong inverse
association between serum leptin levels and nontraumatic
fracture risk even in normal weight subjects [21], as well
as the data that leptin enhances osteoblastogenesis in vitro
[7, 48, 53], exerts a positive eﬀect in fetal bone formation
[54]a n dr e d u c e sb o n el o s si no v a r i e c t o m i z e dr a t s[ 55].
A positive association between leptin/adiponectin ratio
and OC has been reported [17]. In our study, this association
disappeared when eGFR, as an independent variable, was
included in the regression model, and OC was not an
independent predictor of the leptin/adiponectin ratio.
Takentogether,itappearsthatleptin,whichisinvolvedin
multiple endocrine pathways and exerts a wide spectrum of
actions, may lead to opposite eﬀects in diﬀerent metabolic
conditions. The negative eﬀects of leptin on bone may
predominant over the positive ones in obesity when leptin
resistance occurs or when the serum leptin concentration
rises above a certain threshold [50, 56]. In our study group,
there were no obese persons and in 1/3 of patients the
low serum leptin levels were indicative of malnutrition. In
humans, energy deprivation and undernutrition with low
leptinaemia are associated with low bone mass [57]. Our
data suggests that in underweighted and normal weight
persons, lower leptin levels are associated with decrease in
OC, which in turn may further decrease leptin production.
Leptin may have a therapeutic role in treating osteoporosis
in undernourished patients.
Animal studies have indicated that OC regulates in-
sulin metabolism through stimulating the expression ofInternational Journal of Endocrinology 7
adiponectin in adipocytes [1–3]. However, the interrela-
tion between OC and adiponectin remains unclear. Ad-
iponectin and its receptors are expressed on osteoblasts,
and adiponectin in vitro stimulates proliferation and dif-
ferentiation of osteoblasts [6, 8, 58], and OC enhanced
adiponectin expression in cultured adipocytes in a dose-
dependentmanner[2].Experimentaldatainvivo(transgenic
mice models) demonstrated all three a positive, negative or
no eﬀect of adiponectin on bone mass [58, 59]. Clinical
studies reported more often a negative association [22,
60, 61], and also a positive [16] or no correlation [62].
Conﬂictingdataonadiponectin-OCrelationship[16,20,22–
30] together with these discrepancies suggest that the eﬀects
may diﬀer depending on other metabolic factors and clinical
features. In the present study in concordance with other
human studies [11, 17, 20, 30], no correlation was observed
between serum adiponectin and OC. Serum adiponectin was
not associated with BMD of proximal femur in patients
with HF [38]. However, we found a positive relationship
between adiponectin/resistin ratio and OC, suggesting that
a shift in balance towards adiponectin may increase OC
production by counteracting the action of resistin. Of note,
this correlation was observed only when age, sex, BMI, HF
type, parameters of mineral metabolism, and eGFR were
included, as independent variables, in the regression analysis
model. This indicates that serum adiponectin/resistin ratio is
positively associated with OC levels in subjects with similar
above-mentioned characteristics (e.g., when the inﬂuence of
these variables is eliminated).
Our data demonstrate a reciprocal association between
resistin and OC which has not been previously described.
Resistin is expressed in mature human osteoblasts, and
recombinant resistin increases osteoclastigenesis but
only weakly aﬀects diﬀerentiation of preosteoblasts into
osteoblasts [63]. The few clinical studies of resistin-bone
relationship provided conﬂicting data [17, 30, 61, 64]. Our
results are in line with observations that resistin inversely
correlates with BMD in the hip [64], lumbar spine [30],
and radius [65]. Remarkably, the resistin–OC association
in our study became signiﬁcant only after controlling for
25(OH)D and PTH and remained signiﬁcant after further
adjustments for all other covariates except type 2 DM
(Table 2), suggesting that this relationship can be masked by
parameters of mineral metabolism. Indeed, our data showed
that PTH and magnesium were independent determinants
of circulating resistin but not leptin (Table 5) providing a
potential explanation for the “masked” eﬀect.
Of note, after adjusting for type 2 DM, the association
between OC and resistin became nonsigniﬁcant, suggesting
that common signalling and metabolic pathways for OC and
resistin contribute to DM. In line with other studies [66–
69], we found that serum resistin levels in patients with
type 2 DM were signiﬁcantly higher compared to the rest of
the cohort. These observations are consistent with growing
evidence that resistin may be a potential mediator of DM
[70–73] acting, at least partially, through OC.
The relationships between adipokine ratios and OC
have not been systematically examined previously. In this
study, after full adjustment, a signiﬁcant interrelation
between the leptin/resistin ratio and OC and between
adiponectin/resistin ratio and OC was found. However,
analyses of these ratios did not yield additional information
compared to either leptin or resistin measurements.
It should be pointed out that multiple regression analysis
explained only 39.5% of the variance in serum OC, indicat-
ing that factors other than leptin and resistin signiﬁcantly
inﬂuenced the level of OC. We found that both eGFR and
age are independently associated with serum OC as well
as leptin levels, and age is an independent determinant of
resistinaemia. Consistent with other studies, ours showed
that deterioration of kidney function was associated with
higher OC [22] and leptin [74]l e v e l s .T h e r ei sa na g e -
dependent decrease in proliferation and diﬀerentiation of
human osteoblasts, and the highest OC levels have been
reported during adolescence [75]. However, in adults, no
correlation between OC and age was found in some studies
[11], while other described decreased OC levels with age
[76]. In about half (53.3%) of our patients, the serum
OC concentration was low (lower than the low limit of
the reference range) but it was signiﬁcantly and positively
associated with age. It is reasonable to consider that renal
dysfunction may at least partially explain this association, as
we observed a strong negative correlation between age and
eGFR (r =− 0.313, P = 0.001) and eGFR was markedly
decreased (<60mL/min./1.73m2) in 42.6% of our patients.
Thecomplexinterplayofmanymetabolic,renal,andage-
related factors may account for some of the discrepancies
in the literature in regard to adipokine-OC interactions.
It is possible that various combinations of these factors
are causing distinct positive or negative eﬀects. Further
complicating the matter, adiponectin and resistin (as well
as leptin) have been shown to be neuroendocrine hormones
acting directly on the brain [77–81] ,b u ti nc o n tra s tt ol e pti n ,
the centrally mediated eﬀects of adiponectin and resistin
on osteoblast functions are unknown. Moreover, receptors
for resistin and OC still remain unidentiﬁed. To develop an
integrated understanding of adipokine-bone interaction, a
lot more work is needed to be done. There is a growing body
of evidence demonstrating that in osteoporosis impaired
bone metabolism, including OC production and secretion,
does not exist in isolation. It reﬂects the alterations in
a highly complex homeostatic system. Our data indicate
the existence of bidirectional leptin-OC (positive) and
resistin-OC (negative) relationships as a part of a complex
energy metabolism-bone network in older patients with HF.
Figure 1 represents the complex interactions of OC with
adipokines depicting independent signiﬁcant associations
between OC, circulating adipokines, their ratios, age, and
renal status in older patients with HF. Further examination
of the role of these interactions in osteoporotic fractures and
metabolic disorders was warranted.
In regard to the diﬀerences in OC-adipokine interactions
observed in humans and rodents, it should be noted that,
ﬁrstly, the Esp gene, speciﬁcally studied in knockout mouse
models, is a pseudogene in humans [82]. No functional
Esp gene has been identiﬁed in humans, although a close
homologue of Esp is expressed in human osteoblasts [83].
Secondly, in genetically modiﬁed rodents, changes in OC8 International Journal of Endocrinology
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Figure 1: Schematic representation of independent signiﬁcant associations between serum osteocalcin, adipokines, their ratios, renal status,
and age in older patient with hip fracture. LR, leptin/resistin ratio; AR, adiponectin/resistin ratio, eGFR, estimated glomerular ﬁltration rate.
Bidirectional interactions exist between leptin and osteocalcin (positive), between resistin and osteocalcin (negative) and as a consequence
between leptin/resistin ratio and osteocalcin and between adiponectin/resistin ratio and osteocalcin (both positive). Age is an independent
determinant of circulating levels of resistin (positive association) and leptin (negative associations), whereas renal function (eGFR) is
inversely associated with osteocalcin and leptin.
and adipokine levels are much larger than in clinical obser-
vations. Thirdly, the compensatory mechanisms caused by
genetic manipulations are not presented in humans. Fourth-
ly, the eﬀects of ageing and comorbidities have not been
addressed in animal studies.
The notable strength of this study is simultaneous
assessment of three circulating adipokines and OC in the
same cohort and adjustment for a wide range of con-
founding factors, the major limitations of previous studies.
However, multiple comparisons in multivariate regression
analysis may potentiate multicollinearity. After Bonferroni
and Sidak adjustments, all determinants preserved statistical
signiﬁcance, and in all our models (Tables 2–5), the variance
inﬂation factor was between 1.21 and 1.27 indicating that
the amount of multicollinearity was not signiﬁcant. The
main limitation of our study is its cross-sectional design
which precludes conclusions regarding causality. Another
potential limitation of this study is that only total OC
and total adiponectin have been measured. The animal and
in vitro studies showed that uncorboxylated OC exerts an
eﬀect on glucose homeostasis and energy metabolism [1].
However, other studies reported that both carboxylated and
u n c a r b o x y l a t e df o r m so fO Ca n dt o t a lO Ca r ea s s o c i a t e d
with glucose metabolism and insulin resistance [11, 23, 24,
76]. Similarly, some studies concluded that high-molecular
weight (HMW) adiponectin is a better predictor of insulin
resistance and metabolic syndrome, while other studies did
not ﬁnd a signiﬁcant diﬀerence between HMW and total
adiponectin in this regard. We cannot exclude the possibility
that measurements of speciﬁc forms of OC and adiponectin
may provide diﬀerent results. Finally, our study population
represents almost exclusively elderly Caucasians, and the
results may have limited applicability to other age and ethnic
groups.
In conclusion, in older patients with HF, leptin is directly
and resistin inversely associated with circulating OC, and
OC is a signiﬁcant independent determinant of both serum
leptin (positive) and resistin (negative) concentrations.
These suggest bidirectional interactions (crosstalk) between
leptin, resistin and OC as a part of a complex homeostatic
system regulating bone and energy metabolism. Our data do
not support an independent link between adiponectin and
OC in these patients. Further studies should be performed
to evaluate the role of leptin-OC and resistin-OC axes in
osteoporotic fractures and comorbid conditions such as
cardio- and cerebrovascular diseases, diabetes, dementia,
malnutrition, all of which are common in the elderly and
have been shown to be associated with alterations in serum
adipokine and OC levels.
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